Article

Collaboration boosts AAV vectors for gene therapy

Avalanche Biotechnologies Inc. and Lonza have announced a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral (AAV) vectors for gene therapy.

San Francisco and Basel, Switzerland-Avalanche Biotechnologies Inc. and Lonza have announced a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral (AAV) vectors for gene therapy.

Terms of the agreement were not disclosed.

AAV vectors are becoming a promising gene delivery vehicle for the treatment of various diseases, including inherited retinal disorders and age-related macular degeneration.

As part of the agreement, Avalanche and Lonza will make the technology available to third parties and share in the revenue. The Avalanche/Lonza manufacturing collaboration will focus on the development and high-yield production of AAV vectors based on technology that uses stable baculovirus. This technology was licensed by Avalanche from Virovek, which also will play a key role in the collaboration.

“We are delighted to have such a skilled and reputable manufacturing partner in Lonza to help us advance our robust research and development programs using AAV to treat macular degeneration and other blinding diseases,” said Thomas W. Chalberg, PhD, chief executive officer, Avalanche Biotechnologies. “By making our combined technology available to third parties, we hope to allow the entire AAV field to benefit from this best-in-class production process.”

Avalanche Biotechnologies is a privately held biotechnology company that develops technologies and products for sustained delivery of therapeutic proteins to the eye. Lonza is a supplier to the pharmaceutical, healthcare, and life science industries.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.